– CHINA, Hong Kong – Cathay International Holdings Ltd. (LSE: CTI.L), a leading operator and investor in the growing healthcare sector in the People’s Republic of China, is pleased to announce the appointment of Dr. Chan Ching Har Eliza, JP, BBS, LL.D. (Hon), as an independent non-executive director of the Company on 29 March 2016.

Dr. Chan is a Senior Consultant of Zhong Lun Law Firm. She is a Member of the National Committee of the Chinese People’s Political Consultative Conference (CPPCC), a Standing Member of the CPPCC Tianjin Committee, Foreign Economic Affairs Legal Counsel to the Tianjin Municipal People’s Government, and an arbitrator of the China International Economic and Trade Arbitration Commission (CIETAC).

Dr. Chan serves as Chairman of Tseung Kwan O Hospital, Chairman of Pensions Appeal Panel, Member of the Administrative Appeals Board, Investigation Panel Member of the Hong Kong Institute of Certified Public Accountants and the Legal Advisor to The Hong Kong Chinese Enterprises Association. She is also the Chairman of the Hong Kong CPPCC (Provincial) Members Association Limited, Chairman of the Hong Kong CPPCC (Provincial) Members Foundation Limited, Honorary President of The Hong Kong China Chamber of Commerce and a Governor of The Canadian Chamber of Commerce in Hong Kong.

She was also formerly a Member of the Hong Kong Hospital Authority, Chairman of Kowloon Hospital, Chairman of Hong Kong Eye Hospital, Member of the Hong Kong Public Service Commission, Member of the Board of Education, Member of the Hong Kong Examination and Assessment Authority, Member of the Medical Council of Hong Kong, Member of Hospital Governing Committee of Queen Elizabeth Hospital, Council Member of The Hong Kong University of Science and Technology, Member of the Hong Kong Immigration Tribunal and Member of the Board of the Hong Kong Science and Technology Park Corporation.

About Cathay

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and a leading operator and investor in the growing healthcare sector in the People’s Republic of China. The Company and its subsidiaries (collectively the “Group”) aim to leverage on growth opportunities in the strong and growing domestic demand for high quality healthcare products in the PRC and build its portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a strong track record of identifying high-growth potential investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Yangling, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

The Group employs approximately 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company’s offices in Hong Kong and Shenzhen. Cathay also has a hotel investment.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here, the original post =>

Comments are closed.